Brahmi extract (Centalla asiatica) (CAS NO : 93165-26-1)

The global Brahmi extract (Centella asiatica) market is witnessing a profound transformation as the demand for high-purity triterpenoid profiles, specifically asiaticoside and madecassoside, shifts from traditional wellness to advanced dermocosmetics and clinical wound management. Market valuations are projected to expand significantly, reaching approximately USD 1.4 billion by 2033, underpinned by a 5.8% CAGR and a surging B2B requirement for pharmaceutical-grade botanical intermediates. This growth is increasingly concentrated in the Asia-Pacific region, which controls over 55% of global supply, yet faces critical challenges in supply chain resilience due to seasonal cultivation variances that impact 20-25% of annual yields. Leading chemical marketplaces are observing a strategic pivot toward standardised extraction technologies that ensure consistent bioactive concentrations, catering to the "clean beauty" and "nootropic" sectors where regulatory compliance and analytical transparency are paramount for commercial success. As a globally established Brahmi extract (Centella asiatica) supplier with high purity across various grades, we ensure dependable supply, consistent quality, and complete regulatory documentation, including Brahmi extract (Centella asiatica) CoA and Brahmi extract (Centella asiatica) TDS. Beyond supply, we support partners through the entire product lifecycle from route scouting, process and formulation development, and analytical method development to scale-up, process optimisation, and pilot-to-commercial manufacturing. Our teams also assist with GMP-compliant quality assurance, regulatory documentation, and global supply chain and logistics coordination.